Dental extractions in patients treated with intravenous bisphosphonates and risk of osteonecrosis of jaws.

Poster (2012, June)

Aim : Dental extraction remains contra-indicated in patients treated with intravenous (IV) bisphosphonates for oncology reasons because of the high risk of bisphosphonate-related osteonecrosis of the jaw ... [more ▼]

Aim : Dental extraction remains contra-indicated in patients treated with intravenous (IV) bisphosphonates for oncology reasons because of the high risk of bisphosphonate-related osteonecrosis of the jaw (BRONJ). The objective of the present abstract was to present a preventive tooth extraction protocol in patients treated with IV bisphosphonates based on the surgical removal of the alveolar process. The second objective was to identify potential risk factors to develop BRONJ. Material and Methods : 17 patients treated with IV bisphosphonate and needing at least a tooth extraction, were included. A standardized extraction protocol was followed, including alveolectomy of at least 50% of the alveolar process, pre and post-operative antibiotherapy was administrated. The patients were followed for a mean period of 29 months (min:3 -max:62). Results : In all, 17 patients and 22 extraction sites mandible (15), maxilla (7) were involved in the study. No signs of inflamed tissue or necrotic exposed bone in any patient were observed during the follow-up period and the level of comfort for the patient was improved in all cases. Nevertheless, when a careful screening of the healing area was made using a probe, in 4 out of 22 (18,2%) sites, a remaining bone contact was found and appeared to be related location (mandible), duration of biphosphonate treatment and to concomitant. Conclusion : The present cases series suggests that the described extraction protocol in IV biphosphonate patients allowed 100% bone healing and complete soft tissues healing in 81.8% of the extraction sites.The sites that have not fully recovered seemed to be related to different factors. [less ▲]

The Effect of Intravenous Administration of Web 2086 on Paf-Induced Platelet Aggregation in Healthy Friesian Calves

in Veterinary Research Communications (1997), 21(7), 521-531

The in vivo ability of the specific PAF-antagonist WEB 2086, a thienotriazolodiazepine, to inhibit platelet-activating factor (PAF) in cattle was investigated by in vitro determination of platelet ... [more ▼]

The in vivo ability of the specific PAF-antagonist WEB 2086, a thienotriazolodiazepine, to inhibit platelet-activating factor (PAF) in cattle was investigated by in vitro determination of platelet aggregation curves. WEB 2086 was infused intravenously into a group of 5 healthy male Friesian calves in a dose of 3 mg/kg over 1 min. The resultant inhibition peaked between 30 min and 1 h after administration of WEB 2086. The inhibition was significantly reduced after 3 h and became non-significant after 6 h, but maximal pre-treatment aggregation had not been restored by 24 h after the injection of WEB 2086. These results confirm previous results obtained in vitro and suggest that WEB 2086 is a potent antagonist of PAF activity in calves. They also suggest that further clinical studies with WEB 2086 in cattle are desirable. [less ▲]

Inhibition of Paf-Induced Platelet Aggregation by Web 2086 'in-Vitro', an Antagonist to the Receptor for Platelet-Activating Factor, in Bovine

in Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine (1996), 43(7), 399-413

The sensitivity of bovine platelet aggregation in response to PAF stimulation and the ability of WEB 2086 (a thieno-triazolodiazepine) to inhibit response to PAF-induced platelet aggregation were ... [more ▼]

The sensitivity of bovine platelet aggregation in response to PAF stimulation and the ability of WEB 2086 (a thieno-triazolodiazepine) to inhibit response to PAF-induced platelet aggregation were investigated in the blood from five healthy male Belgian Blue calves. The recorded response to PAF showed a plateau which was dependent on the PAF concentration. Platelet aggregation induced by PAF consists of two mechanisms: reversible and irreversible aggregations which are accompanied by the release of platelet granule contents. Reversible aggregation occurred above (2 . 10(-9) mol/l) PAF, and irreversible aggregation occurred above (2 . 10(-7) mol/l) PAF. Addition of WEB 2086 to bovine platelets in vitro induced a rightward shift in the dose-response curve to PAF. WEB 2086 inhibited PAF-induced aggregation in a competitive reversible manner (pA2 = 7.61). The results of our study show that PAF induces platelet aggregation in platelet-rich plasma (PRP) and that addition of WEB 2086 to bovine platelets in vitro inhibits PAF-induced Platelet Aggregation. [less ▲]